Hutchison China Meditech Limited Director's Share Dealing (0984I)

TIDMHCM

RNS Number : 0984I

Hutchison China Meditech Limited

19 March 2018

Director's Share Dealing

London: Monday, March 19, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on March 14, 2018 at an average price of US$36.11 per ADS.

Following the above purchase, Dr Eldar is interested in 8,993 ADSs and 1,900 Ordinary Shares, representing approximately 0.0096% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1      Details of the person discharging managerial responsibilities/person closely associated 
-----  --------------------------------------------------------------------------------------------------------------- 
  a)     Name                                                     Dr Dan Eldar 
-----  -------------------------------------------------------  ------------------------------------------------------ 
 2      Reason for the notification 
-----  --------------------------------------------------------------------------------------------------------------- 
  a)     Position/status                                          Non-executive Director 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  b)     Initial notification/Amendment                           Initial notification 
-----  -------------------------------------------------------  ------------------------------------------------------ 
 3      Details of the issuer, emission allowance market participant, auction platform, auctioneer 
         or auction monitor 
-----  --------------------------------------------------------------------------------------------------------------- 
  a)     Name                                                     Hutchison China MediTech Limited 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  b)     LEI                                                      2138006X34YDQ6OBYE79 
-----  -------------------------------------------------------  ------------------------------------------------------ 
 4      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
         each type of transaction; (iii) each date; and (iv) each place where transactions have been 
         conducted 
-----  --------------------------------------------------------------------------------------------------------------- 
  a)     Description of the financial instrument, type of         ADS each representing one half of one Ordinary Share 
         instrument                                               of US$1.00 
         Identification code                                      ADS ISIN: US44842L1035 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  b)     Nature of the transaction                                Acquisition of 2,768 ADSs on March 14, 2018 at an 
                                                                  average price of US$36.11 per ADS 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  c)     Price(s) and volume(s)                                    Price(s)    Volume(s) 
                                                                   ----------  ---------- 
                                                                    US$36.12      2,700 
                                                                   ----------  ---------- 
                                                                    US$35.74       68 
                                                                   ----------  ---------- 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  d)     Aggregated information 
          -  Aggregated volume                                               N/A 
          -  Price 
-----  -------------------------------------------------------  ------------------------------------------------------ 
 
  e)     Date of the transaction                                   2018-03-14 
-----  -------------------------------------------------------  ------------------------------------------------------ 
  f)     Place of the transaction 
                                                                   Nasdaq Stock Market 
-----  -------------------------------------------------------  ------------------------------------------------------ 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate 
 Finance & Development                       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson     [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications               [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications              [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                   [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson          [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                  [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLIFERVRIALIT

(END) Dow Jones Newswires

March 19, 2018 03:10 ET (07:10 GMT)